PRINCETON, N.J., Nov. 13 /PRNewswire-FirstCall/ -- China Biopharma, Inc. , a biopharmaceutical company focused on developing and distributing human vaccine products in China, announced today that through its subsidiary, Hainan CITIC Biopharmaceutical Development Co., Ltd., it has completed the delivery of 1.5 Million doses of flu vaccine in China.
Chairman and CEO of China Biopharma, Inc., Peter Wang, stated, “We are very pleased that our flu vaccine was among the first to be made available to the general public in China for the 2006-2007 Flu Season. The (Chinese) Centers for Disease Control (CDCs) have set a rigorous blueprint to increase the accessibility and affordability to influenza vaccine programs nationwide. Our vision is to become one of China’s leading providers of pandemic and seasonal influenza vaccines. Now that we have successfully delivered our first batch of flu vaccines to local CDCs, insurance companies, hospitals, and other facilities, we believe we are on track to deliver a total of three million doses of vaccine by year-end 2006.”
About China Biopharma Inc.
China Biopharma Inc. is a fast-growing biopharmaceutical company based in China. Through its operating subsidiaries, Zhejiang Tianyuan Biotech Co., Ltd. and Hainan CITIC Biopharmaceutical Development Co., Ltd., the Company develops and distributes human vaccine products throughout the world’s most populated country, China. Products include human vaccines against influenza, hemorrhagic fever, and Japanese Encephalitis. Leveraging its investment and ownership of local Chinese biopharmaceutical companies, and partnerships with international vaccine providers, China Biopharma is building a highly-competitive platform for growth in China as well as new markets, including the U.S. and Europe. For more information, visit its website at http://www.chinabiopharma.com.cn.
Safe Harbor Statement
Some of the statements made in this press release discuss future events and developments, including the Company’s future business strategy and its ability to generate revenue, income and cash flow, and should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These “forward-looking” statements can generally be identified by words such as “expect,” “anticipate,” “believe,” “estimate,” “intend,” “plan,” and similar expressions. These statements involve a high degree of risk and uncertainty that exists in the Company’s operations and business environment and are subject to change based on various factors that could cause actual Company results, performance, plans, goals and objectives to differ materially from those contemplated or implied in these forward-looking statements. Actual results may be different from anticipated results for a number of reasons, including the Company’s new and uncertain business model, uncertainty regarding acceptance of the Company’s products and services and the Company’s limited operating history.
CONTACT: At the Company: George Ji China Biopharma, Inc. Tel: +1 (609) 651-8588 ir@chinabiopharma.nethttp://www.chinabiopharma.com.cn Investor Relations: OTC Financial Network Peter Clark Tel: +1 (781) 444-6100x629 peter@otcfn.comhttp://www.otcfn.com/cbpc
China Biopharma, Inc.
CONTACT: George Ji of China Biopharma, Inc., +1-609-651-8588,ir@chinabiopharma.net; or Investor Relations: Peter Clark of OTC FinancialNetwork, for China Biopharma, Inc., +1-781-444-6100, ext. 629,peter@otcfn.com
